Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.

Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. Click here to read more.

The auto industry is flashing warning lights on the state of the U.S. economy. Automakers' profits are getting squeezed by tariffs. A subprime auto lender recently collapsed, and some car retailers ...

Acumatica has announced the general availability of its 2025 R2 ERP Platform. The R2 release features new and updated enhancements that improve usability, ...

Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.

Jupiter Endovascular, Inc. announced that its Vertex catheter has received FDA 510(k) clearance for the insertion of endovasc ...

The three-lap event, one of eight that day, was won by FC Pycroft in an unusual-looking Jaguar SS100, seeing off a small ...

VX-993 was generally safe and well tolerated at all doses studied in the trial. The overall incidence of adverse events on VX-993 was similar to placebo. The majority of the AEs were mild or moderate ...

Veronica Beagle is the managing editor for Education at Forbes Advisor. She completed her master’s in English at the University of Hawai‘i at Mānoa. Before coming to Forbes Advisor she worked on ...

The Post welcomes letters up to 250 words on topics of general interest. Letters must include full name, home address, day and evening phone numbers, and may be edited for length, grammar and accuracy ...